Biosimilars Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026

The Business Research Company's Biosimilars Global Market Report 2022– Market Size, Trends, And Global Forecast 2022-2026

LONDON, GREATER LONDON, UK, February 11, 2022 /EINPresswire.com/ -- According to ‘Biosimilars Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026’ published by The Business Research Company, the biosimilars market size is expected to grow from $15.67 billion in 2021 to $19.10 billion in 2022 at a compound annual growth rate (CAGR) of 21.8%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The biosimilar market is expected to reach $42.30 billion in 2026 at a CAGR of 22%. The rising prevalence of chronic diseases such as arthritis, asthma, and cancer is expected to be a major driver of the biosimilars market.

Want to learn more on the biosimilars market growth? Request for a Sample now:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2807&type=smp

The global biosimilars market consists of sales of biosimilars and related services that are used to treat chronic diseases such as diabetes, arthritis, and cancer. Biosimilars are pharmaceuticals that are manufactured using cell lines and offer no clinical difference as compared to biologics. Biosimilars are made once the patent of biologics is expired.

Global Biosimilars Market Trends
Production of new insulin biosimilars is trending in the biosimilars market. The key players operating in the biosimilars market are investing in creating a biosimilar of insulin. This is also promoting competition among various biosimilar manufacturers.

Global Biosimilars Market Segments
The global biosimilars market is segmented:
By Product: Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins
By Type: Human Growth Hormone, Erythropoietin, Monoclonal Antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor, Others
By Application: Oncology, Chronic and Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Others
By Geography: The global biosimilar market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Among these regions, North America accounts for the largest share.

Read more on the global biosimilars market report at:
https://www.thebusinessresearchcompany.com/report/biosimilars-global-market-report

Biosimilars Global Market Report 2022 is one of a series of new reports from The Business Research Company that provides market overviews, analyzes and forecasts market size and growth for the global biosimilars market, share, segments and geographies, trends, players, leading competitor revenues, profiles and market shares. The biosimilars market report identifies top countries and segments for opportunities and strategies based on market trends and key competitors’ approaches.

TBRC’s Biosimilars Global Market Report 2022 includes information on the following:
Data Segmentations: Market Size, Global, By Region and Country, Historic and Forecast, and Growth Rates for 60 Geographies

Key Market Players: Pfizer, Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Boehringer Ingelheim, Elli Lilly and Company, Mylan N.V., Sanofi, STADA Arzneimittel, Sandoz International, Samsung Bioepis, Teva Pharmaceuticals, Apotex, AMEGA Biotech S.A., Bioton S.A., Innovent Biologics International, Allergan plc, BioXpress Therapeutics, 3SBio, Intas Biopharmaceuticals, Lupin Merck, Novartis, Ratiopharm, Wockhardt, Zydus Cadila, Allergan Plc., Hospira International., Actavis International., Johnson & Johnson and Roche.

Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.

Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
And so much more.

Looking for something else? Here is a list of similar reports by The Business Research Company:
Biosimilar Lymphocyte Modulator Global Market Report 2022
https://www.thebusinessresearchcompany.com/report/biosimilar-lymphocyte-modulator-global-market-report

Biosimilar Hormones Global Market Report 2022
https://www.thebusinessresearchcompany.com/report/biosimilar-hormones-global-market-report

Biosimilar Interleukins Global Market Report 2022
https://www.thebusinessresearchcompany.com/report/biosimilar-interleukins-global-market-report

About The Business Research Company
The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.

Check out our:
LinkedIn: https://bit.ly/3b7850r
Twitter: https://bit.ly/3b1rmjS
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: http://blog.tbrc.info/

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.